Swiss pharma giant Novartis (NOVN: VX) on Saturday presented new real-world data on its Leqvio (inclisiran) at the 2024 American College of Cardiology's Annual Scientific Session & Expo.
The data demonstrated the early addition of twice-yearly Leqvio to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone.
Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze